A Study of Gastric Delay in Migraine Patients (3207-003)
Phase 1
Completed
- Conditions
- Migraine Disorders
- Interventions
- Drug: MK3207
- Registration Number
- NCT00548353
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
A study to assess safety and PK of an investigational drug in migraine patients during and between migraine attacks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
- Non-smoking male or female between 18 to 45 years of age
- Patient typically has between 2 and 10 migraine attacks per month, rated as moderate or severe
Read More
Exclusion Criteria
- Patient has any other medical conditions other than migraine
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 MK3207 MK3207 Orally administered to patients with water. During each period (with and without acute migraine).
- Primary Outcome Measures
Name Time Method Safety in migraine patients 12 Weeks
- Secondary Outcome Measures
Name Time Method PK in migraine patients 12 Weeks